Researchers describe mechanisms that trigger NASH and liver cancer
Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable. A study conducted at the Spanish National Cancer Research...
View ArticlePrimary liver carcinoma may be misclassified based solely on major imaging...
A study released in the July 2016 issue of the American Journal of Roentgenology found that biphenotypic primary liver carcinoma (also called hepatocholangiocarcinoma) may be misclassified as...
View ArticleSelenium status influence cancer risk
As a nutritional trace element, selenium forms an essential part of our diet. In collaboration with the International Agency for Research on Cancer, researchers from Charité - Universitätsmedizin...
View ArticleSpecial T cells that target solid tumors offer potential treatment for...
Adoptive cell-therapies, in which a patient's own immune cells are used to recognize and target tumors, have shown breakthrough results for patients with certain B-cell malignancies, or cancers of the...
View ArticlePhysical activity reduces intrahepatic lipid content
(HealthDay)—For patients with nonalcoholic fatty liver disease (NAFLD) and underlying metabolic disorders, physical activity is associated with a reduction in intrahepatic lipid content and markers of...
View ArticleHOMA2-IR tied to hepatocellular carcinoma risk in hepatitis B
(HealthDay)—Insulin resistance assessed by homeostasis model assessment index (HOMA2-IR) correlates with the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV)...
View ArticleDiabetes ups risk of HCC, death in patients with hepatitis C
(HealthDay)—For hepatitis C virus (HCV)-infected patients, diabetes mellitus (DM) is associated with increased risk of hepatocellular carcinoma (HCC) development and all-cause mortality, according to a...
View ArticleOne more piece in the puzzle of liver cancer identified
Manuela Baccarini and her team at the Max F. Perutz Laboratories (MFPL) of the University of Vienna and Medical University of Vienna are one step closer to unraveling the mechanisms behind liver...
View ArticleNon-liver-related critical events down with SVR in HCV+Cirrhosis
(HealthDay)—For patients with hepatitis C virus (HCV) infection and biopsy-proven cirrhosis, sustained viral response (SVR) is associated with a reduction in critical events, both liver and non-liver...
View ArticleSuccessful phase 3 trial of drug for liver cancer
An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had...
View ArticleRisk of liver cancer low in patients with cirrhosis, study finds
The results of a study by researchers at The University of Nottingham suggest that the risk of liver cancer in patients with cirrhosis may be much lower than previously thought.
View ArticleGold standard monitoring of HCC in patients with cirrhosis is cost-effective
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. A new analysis indicates that following screening guidelines for HCC in cirrhotic patients is lifesaving and...
View ArticleLiver tumor growth in mice slowed with new chemo-immunotherapy treatment
Hepatocellular carcinoma is the most common form of liver cancer, but treatment options are limited and many patients are diagnosed in late stages when the disease can't be treated. Now, University of...
View ArticlePost-RFA mortality up for ESRD patients who receive dialysis
(HealthDay)—For patients with end-stage renal disease (ESRD), receipt of hemodialysis (HD) is associated with increased mortality after radiofrequency ablation (RFA) for hepatocellular carcinoma,...
View ArticleIs DAA therapy for hepatitis C associated with an increased risk of liver...
According to data from eight studies being presented at The International Liver Congress 2017 in Amsterdam, The Netherlands, there remains continued debate on whether patients are at risk of developing...
View ArticleNivolumab produces durable responses and long-term survival in severe liver...
Results from the CheckMate 040 study presented today found that nivolumab, an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates,...
View ArticleNew studies refocus attention on the genotoxicity of AAV vectors in gene therapy
A growing number of preclinical studies in mice suggests that therapeutic gene delivery using recombinant adeno-associated viral vectors (rAAVs) can cause insertional mutagenesis and increase the risk...
View ArticleSubcirrhotic liver stiffness cuts HCC risk in hepatitis B
(HealthDay)—For patients with chronic hepatitis B (CHB), achievement of subcirrhotic range of liver stiffness (sc-LS) with antiviral therapy (AVT) is associated with reduced risk of hepatocellular...
View ArticleIdentifying a new type of liver tumor
Investigators at Children's Hospital Los Angeles have succeeded in better defining a rare pediatric malignant liver disease—a necessary step in achieving an optimum treatment.
View ArticleLiver cancer patients can start with lower dose of chemotherapy and live just...
Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not...
View Article